Efficacy and Safety of a Urate Lowering Regimen in Primary Gout

REFERENCES

• Terkeltaub, R.A. Gout. N. Engl. J. Med. 2003, 349, 1647–1655.
   PubMed Web of Science ®Google Scholar
• Moreland, L.W. Febuxostat: treatment for hyperuricemia and gout? New Engl. J. Med. 2005, 353, 2505–2507.
   PubMed Web of Science ®Google Scholar
• Terkeltaub, R. Update in gout: new therapeutic strategies and options. Nat. Rev. Rheumatol. 2010, 6, 30–98.
   PubMed Web of Science ®Google Scholar
• Becker, M.A.; Schumacher, H.R.; Wortmann, R.L.; MacDonald, P.A.; Eustace, D.; Palo, W.A.; Streit, J.; Joseph-Ridge, N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 2005, 353, 2450–2461.
   PubMed Web of Science ®Google Scholar
• Becker, M.A.; Schumacher, H.R.; Espinoza, L.R.; Wells, A.F.; MacDonald, P.; Lloyd, E.; Lademacher, C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. Ther. 2010, 12, R63.
   PubMed Web of Science ®Google Scholar
• Schumacher, H.R.; Becker, M.A.; Wortmann, R.L.; MacDonald, P.A.; Hunt, B.; Streit, J.; Lademacher, C.; Joseph-Ridge, N.; Effects of febuxostat versus allopurinol and placebo in reduncing serum urate in subjects with hiperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arth. Rheum. 2008, 59, 1540–1548.
   PubMed Web of Science ®Google Scholar
• Zhang, W.; Doherty, M.; Bardin, T.; Pascual,E; Barskova, V.; Conaghan, P.; Gerster, J.; Jacobs, J.; Leeb, B.; Lioté, F.; McCarthy, G.; Netter, P.; Nuki, G.; Perez-Ruiz, F.; Pignone, A.; Pimentão, J.; Punzi, L.; Roddy, E.; Uhlig, T.; Zimmermann-Gòrska, I. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 2006, 65, 1312–1324.
   PubMed Web of Science ®Google Scholar
• Reinders, M.K.; van Roon, E.N.; Jansen, T.L.; Delsing, J.; Griep, E.N.; Hoekstra, M.; Hoekstra, M.; van de Laar, M.A.; Brouwers, J.R. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann. Rheum. Dis. 2009, 68, 51–56.
   PubMed Web of Science ®Google Scholar
• Reinders, M.K.; Haagsma, C.; Jansen, T.L.; van Roon, E.N.; Delsing, J.; van de Laar, M.A.; Brouwers, J.R. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann. Rheum. Dis. 2009, 68, 892–897
   PubMed Web of Science ®Google Scholar
• Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S.; Kaldas, M.; Gogia, M.; Perez-Ruiz, F.; Taylor, W.; Lioté, F.; Choi, H.; Singh, J.A.; Dalbeth, N.; Kaplan, S.; Niyyar, V.; Jones, D.; Yarows, S.A.; Roessler, B.; Kerr, G.; King, C.; Levy, G.; Furst, D.E.; Edwards, N.L.; Mandell, B.; Schumacher, H.R.; Robbins M.; Wenger, N.; Terkeltaub, R. 2012 American College of Rheumatology Guidelines for management of gout. Part 1: systematic no pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arth. Care Res. 2012, 64, 1431–1446.
   PubMed Web of Science ®Google Scholar
• Puig, J.G.; Torres, R.J.; de Miguel, E.; Sánchez, A.; Bailén, R.; Banegas, J.R. Uric acid excretion in normal subjects: a nomogram to assess the mechanisms underlying purine metabolic disorders. Metabolism. 2012, 61, 512–518.
   PubMed Web of Science ®Google Scholar
• Wallace, S.L.; Robinson, H.; Masi, A.T.; Decker, J.L.; McCarty, D.J.; Yü, T.F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977, 20, 895–900.
   PubMed Web of Science ®Google Scholar
• Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; Narkiewicz, K.; Ruilope, L.; Rynkiewicz, A.; Schmieder, R.E.; Boudier, H.A.; Zanchetti, A.; ESH-ESC task force on the management of arterial hypertension. J. Hypertens 2007, 25, 1751–1762.
   PubMed Web of Science ®Google Scholar
• Borstad, G.C.; Bryant, L.R.; Abel, M.P.; Scroggie, D.A.; Harris, M.D.; Alloway, J.A. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 2004, 31, 2429–2432.
   PubMed Web of Science ®Google Scholar
• Grundy, S.M.; Brewer, H.B.; Clleman, J.I.; Smith, S.C.; Lenfant, C.; American Heart Association, National Heart, Lung and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004, 27, 433–438.
   Web of Science ®Google Scholar
• Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S.; Kaldas, M.; Gogia, M.; Perez-Ruiz, F.; Taylor, W.; Lioté, F.; Choi, H.; Singh, J.A.; Dalbeth, N.; Kaplan, S.; Niyyar, V.; Jones, D.; Yarows, S.A.; Roessler, B.; Kerr, G.; King, C.; Levy, G.; Furst, D.E.; Edwards, N.L.; Mandell, B.; Schumacher, H.R.; Robbins, M.; Wenger, N.; Terkeltaub, R.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis. Care Res. 2012, 64, 1431–1446.
   PubMed Web of Science ®Google Scholar
• López-Jiménez, M.; Vigil-Medina, L.; Condés-Moreno, E.; García-Carretero, R.; Fernández-Mejías, C. Ruiz-Galiana, J. Uricemia and metabolic syndrome in patients with arterial hypertension. Rev. Clin. Esp. 2012, 212, 425–431.
   PubMed Web of Science ®Google Scholar
• Casado, J.; Montero, M.; Formiga, F.; Camafort, M.; Sánchez, C.; Muela, A.; Díez, J.; Pérez, J.I.; Grupo RICA. Renal function in patients with heart failure: prognostic value. Rev. Clin. Esp. 2012, 212, 119–126.
   PubMed Web of Science ®Google Scholar